News

Blisibimod Seen to Lower Urine Protein Levels in Patients with Renal Involvement in Phase 3 Trial

Results of a Phase 3 clinical trial of blisibimod, by Anthera Pharmaceuticals, found that treatment significantly reduces proteinuria — excess proteins in the urine — in patients with systemic lupus erythematous (SLE). Like many B-cell mediated autoimmune diseases, lupus is associated with elevated levels of B-cell activating factor (BAFF). Blisibimod is…

Cardiac Tamponade Is Common but Treatable Manifestation of Lupus, Study Finds

Cardiac tamponade, the accumulation of fluid around the heart, affects nearly 6 percent of lupus patients in India, a new retrospective study shows. But researchers found new risk factors that predict this condition, which may help identify patients at risk. Treatment with high-dose immunosuppressives reduced the risk for fluid reaccumulation…

Inhibiting cGAS Enzyme May Reduce Autoimmune Responses, Mouse Study Shows

Inhibition of a natural enzyme that works as a sensor for virus and bacteria invasions may reduce inflammation associated with autoimmune diseases, including systemic lupus erythematosus, according to a recent study. The findings, reported in the study “Small molecule inhibition of cGAS reduces interferon expression in primary macrophages…

LFA Appoints New Chair of Medical-Scientific Advisory Council

Karen H. Costenbader, MD, is the new chairwoman of the medical-scientific advisory council of the Lupus Foundation of America (LFA). Chairman of the LFA’s national board of directors, Conrad Gehrmann, announced the appointment earlier this week. Costenbader will lead the multi-disciplinary group of lupus experts to address unmet needs…